NeoGenomics Presents RaDaR Assay Data at 2025 SABCS for Breast Cancer Monitoring
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Should l Buy NEO?
Source: Newsfilter
- Research Presentation: NeoGenomics will showcase new data on its RaDaR®1.0 assay at the 2025 SABCS, emphasizing its critical role in monitoring molecular residual disease in early breast cancer, which could advance precision medicine.
- Clinical Trial Progress: The SURVIVE HERoes Phase III trial will explore the application of RaDaR testing in molecular relapse monitoring, and positive results could provide new strategies for personalized treatment, enhancing patient survival rates.
- Long-term Tracking Study: Five-year follow-up data from the CLEVER trial show that RaDaR-detected ctDNA is often present months before clinical recurrence, highlighting its potential in monitoring long-term risks and possibly changing standards for post-treatment care in breast cancer.
- Industry Impact: CEO Tony Zook stated that these studies provide crucial evidence for integrating MRD insights into routine oncology care, potentially enhancing the treatment capabilities of community oncologists.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NEO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NEO
Wall Street analysts forecast NEO stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 11.170
Low
12.00
Averages
14.00
High
16.00
Current: 11.170
Low
12.00
Averages
14.00
High
16.00
About NEO
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeoGenomics to Announce Q4 Earnings on February 17
- Earnings Announcement Date: NeoGenomics is set to release its Q4 earnings on February 17 before market open, with a consensus EPS estimate of $0.04, indicating stable profitability year-over-year.
- Revenue Growth Expectations: The anticipated revenue for Q4 is approximately $190 million, reflecting a 9.4% year-over-year increase, which highlights the ongoing demand and market expansion capabilities in community oncology.
- Historical Performance Review: Over the past two years, NeoGenomics has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, demonstrating reliability in financial forecasting.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw no upward revisions and two downward adjustments, while revenue estimates experienced one upward revision and two downward adjustments, indicating a cautious market outlook on the company's future performance.
See More
NeoGenomics to Report Q4 and Full Year 2025 Results
- Earnings Report Schedule: NeoGenomics will announce its fourth quarter and full year 2025 financial results before the U.S. market opens on February 17, 2026, which is expected to provide investors with critical financial data and business highlights.
- Management Conference Call: The company's management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights, enhancing transparency and engaging with investors.
- Webcast Access: Investors can access the live webcast through the Investor Relations section of the company’s website, with a replay available shortly after the call, ensuring that those unable to attend live can still obtain the information.
- Global Laboratory Network: NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in the U.S. and the U.K., providing comprehensive cancer genetics testing and information services to oncologists and hospital systems, further solidifying its leadership in the oncology diagnostics field.
See More
NeoGenomics (NEO) Projects $727 Million Revenue for 2025 with CFO Transition
- Revenue Growth Outlook: NeoGenomics anticipates approximately $190 million in revenue for Q4 2025, reflecting an 11% year-over-year increase, indicating sustained demand in the cancer testing sector and reinforcing its position as the partner of choice.
- Annual Revenue Projection: The company expects full-year 2025 revenue to reach $727 million, representing a 10% year-over-year growth, showcasing its ongoing potential in precision medicine, particularly in innovative cancer treatment testing.
- Executive Transition: The company announced a CFO succession plan with Abhishek Jain set to assume the CFO role on March 2, 2026, while current CFO Jeff Sherman transitions to Executive Vice President, ensuring a smooth leadership transition to support future growth strategies.
- Financial Stability: Jain's extensive experience in the life sciences sector is expected to enhance NeoGenomics' financial discipline and operational efficiency, further driving long-term value creation in the advanced cancer testing market.
See More
NeoGenomics to Present at 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: NeoGenomics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, showcasing its expertise in oncology diagnostic solutions, which is expected to attract investor and industry attention.
- Schedule Details: The management's presentation is set for 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time, providing an opportunity for investor interaction aimed at enhancing the company's visibility in the precision medicine sector.
- Online Access: Interested parties can access live and archived webcasts of the sessions on the company's website, increasing transparency and facilitating communication with potential investors.
- Company Background: NeoGenomics is a leading cancer diagnostics company specializing in cancer genetics testing and information services, offering a comprehensive oncology testing menu that serves hospital systems and pharmaceutical firms, highlighting its significance in the precision medicine landscape.
See More
Ryvyl Inc Announces 1-for-35 Reverse Split, Shares Plunge 14.4%
- Reverse Split Announcement: Ryvyl Inc's announcement of a 1-for-35 reverse stock split to regain Nasdaq's $1 minimum bid compliance led to a pre-market plunge of 14.4% in share price to $0.13, indicating a significant loss of investor confidence and potential liquidity issues.
- Market Reaction: Following the reverse split news, Ryvyl's shares fell sharply, reflecting market concerns about the company's future prospects, which could hinder its ability to raise capital and maintain competitive positioning.
- Other Stock Movements: Shares of Mink Therapeutics and SMX dropped 13.4% and 8.2% respectively, illustrating a broader market sentiment decline that may negatively impact investor confidence across related sectors.
- Industry Impact: Despite NeoGenomics' 7.1% decline in share price, the appointment of industry veteran John P. Kenny to its Board may provide a strategic turning point for the company, potentially enhancing its competitive edge in the diagnostics and lab services market.
See More
NeoGenomics Appoints Jack Kenny to Board of Directors, Enhancing Leadership in Oncology Diagnostics
- New Board Appointment: NeoGenomics has appointed Jack Kenny, a veteran with over three decades of industry experience, to its Board of Directors, filling the vacancy left by Alison Hannah, aiming to leverage his extensive commercial and operational background to drive innovation in cancer diagnostics.
- Industry Leadership: Kenny previously served as CEO of Meridian Bioscience, where he led the development of innovative diagnostic products, and his experience is expected to help NeoGenomics capitalize on emerging opportunities in next-generation cancer testing, particularly NGS and MRD.
- Strategic Guidance: Board Chair Lynn Tetrault stated that Kenny's addition will bring leadership in high-performance commercial teams, further enhancing the company's competitiveness in the cancer diagnostics market.
- Acknowledgment of Predecessor: Tetrault also expressed gratitude to Alison Hannah for her strategic guidance over the past decade, emphasizing her unwavering commitment to the company's mission and invaluable contributions.
See More
NeoGenomics to Announce Q4 Earnings on February 17
- Earnings Announcement Date: NeoGenomics is set to release its Q4 earnings on February 17 before market open, with a consensus EPS estimate of $0.04, indicating stable profitability year-over-year.
- Revenue Growth Expectations: The anticipated revenue for Q4 is approximately $190 million, reflecting a 9.4% year-over-year increase, which highlights the ongoing demand and market expansion capabilities in community oncology.
- Historical Performance Review: Over the past two years, NeoGenomics has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, demonstrating reliability in financial forecasting.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw no upward revisions and two downward adjustments, while revenue estimates experienced one upward revision and two downward adjustments, indicating a cautious market outlook on the company's future performance.
See More
NeoGenomics to Report Q4 and Full Year 2025 Results
- Earnings Report Schedule: NeoGenomics will announce its fourth quarter and full year 2025 financial results before the U.S. market opens on February 17, 2026, which is expected to provide investors with critical financial data and business highlights.
- Management Conference Call: The company's management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights, enhancing transparency and engaging with investors.
- Webcast Access: Investors can access the live webcast through the Investor Relations section of the company’s website, with a replay available shortly after the call, ensuring that those unable to attend live can still obtain the information.
- Global Laboratory Network: NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in the U.S. and the U.K., providing comprehensive cancer genetics testing and information services to oncologists and hospital systems, further solidifying its leadership in the oncology diagnostics field.
See More
NeoGenomics (NEO) Projects $727 Million Revenue for 2025 with CFO Transition
- Revenue Growth Outlook: NeoGenomics anticipates approximately $190 million in revenue for Q4 2025, reflecting an 11% year-over-year increase, indicating sustained demand in the cancer testing sector and reinforcing its position as the partner of choice.
- Annual Revenue Projection: The company expects full-year 2025 revenue to reach $727 million, representing a 10% year-over-year growth, showcasing its ongoing potential in precision medicine, particularly in innovative cancer treatment testing.
- Executive Transition: The company announced a CFO succession plan with Abhishek Jain set to assume the CFO role on March 2, 2026, while current CFO Jeff Sherman transitions to Executive Vice President, ensuring a smooth leadership transition to support future growth strategies.
- Financial Stability: Jain's extensive experience in the life sciences sector is expected to enhance NeoGenomics' financial discipline and operational efficiency, further driving long-term value creation in the advanced cancer testing market.
See More
NeoGenomics to Present at 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: NeoGenomics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, showcasing its expertise in oncology diagnostic solutions, which is expected to attract investor and industry attention.
- Schedule Details: The management's presentation is set for 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time, providing an opportunity for investor interaction aimed at enhancing the company's visibility in the precision medicine sector.
- Online Access: Interested parties can access live and archived webcasts of the sessions on the company's website, increasing transparency and facilitating communication with potential investors.
- Company Background: NeoGenomics is a leading cancer diagnostics company specializing in cancer genetics testing and information services, offering a comprehensive oncology testing menu that serves hospital systems and pharmaceutical firms, highlighting its significance in the precision medicine landscape.
See More
Ryvyl Inc Announces 1-for-35 Reverse Split, Shares Plunge 14.4%
- Reverse Split Announcement: Ryvyl Inc's announcement of a 1-for-35 reverse stock split to regain Nasdaq's $1 minimum bid compliance led to a pre-market plunge of 14.4% in share price to $0.13, indicating a significant loss of investor confidence and potential liquidity issues.
- Market Reaction: Following the reverse split news, Ryvyl's shares fell sharply, reflecting market concerns about the company's future prospects, which could hinder its ability to raise capital and maintain competitive positioning.
- Other Stock Movements: Shares of Mink Therapeutics and SMX dropped 13.4% and 8.2% respectively, illustrating a broader market sentiment decline that may negatively impact investor confidence across related sectors.
- Industry Impact: Despite NeoGenomics' 7.1% decline in share price, the appointment of industry veteran John P. Kenny to its Board may provide a strategic turning point for the company, potentially enhancing its competitive edge in the diagnostics and lab services market.
See More
NeoGenomics Appoints Jack Kenny to Board of Directors, Enhancing Leadership in Oncology Diagnostics
- New Board Appointment: NeoGenomics has appointed Jack Kenny, a veteran with over three decades of industry experience, to its Board of Directors, filling the vacancy left by Alison Hannah, aiming to leverage his extensive commercial and operational background to drive innovation in cancer diagnostics.
- Industry Leadership: Kenny previously served as CEO of Meridian Bioscience, where he led the development of innovative diagnostic products, and his experience is expected to help NeoGenomics capitalize on emerging opportunities in next-generation cancer testing, particularly NGS and MRD.
- Strategic Guidance: Board Chair Lynn Tetrault stated that Kenny's addition will bring leadership in high-performance commercial teams, further enhancing the company's competitiveness in the cancer diagnostics market.
- Acknowledgment of Predecessor: Tetrault also expressed gratitude to Alison Hannah for her strategic guidance over the past decade, emphasizing her unwavering commitment to the company's mission and invaluable contributions.
See More
